Nova Eye Medical Limited (EYE.AX)
- Previous Close
0.2700 - Open
0.2700 - Bid 0.2700 x 3603200
- Ask 0.2750 x 12700
- Day's Range
0.2650 - 0.2750 - 52 Week Range
0.1150 - 0.3250 - Volume
150,249 - Avg. Volume
510,966 - Market Cap (intraday)
62.919M - Beta (5Y Monthly) 0.95
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0800 - Earnings Date Feb 23, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date Jul 21, 2020
- 1y Target Est
0.60
Nova Eye Medical Limited designs, develops, manufactures, markets, and sells surgical devices for the treatment of glaucoma in Australia, the United States, Europe, the Asia Pacific, and internationally. It offers iTrack, a glaucoma surgical device to reduce intraocular pressure in adult patients with open-angle glaucoma; iTrack Advance, a canaloplasty microcatheter; Molteno3, a glaucoma drainage device to treat patients with severe or complex glaucoma; and 2RT, a proprietary laser technology to treat patients in early/intermediate age-related macular degeneration. The company was formerly known as Ellex Medical Lasers Limited and changed its name to Nova Eye Medical Limited in July 2020. Nova Eye Medical Limited was incorporated in 1970 and is headquartered in Kent Town, Australia.
www.nova-eye.comRecent News: EYE.AX
Performance Overview: EYE.AX
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: EYE.AX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: EYE.AX
Valuation Measures
Market Cap
62.92M
Enterprise Value
61.52M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
2.68
Price/Book (mrq)
3.70
Enterprise Value/Revenue
3.28
Enterprise Value/EBITDA
-7.69
Financial Highlights
Profitability and Income Statement
Profit Margin
-76.24%
Return on Assets (ttm)
-23.09%
Return on Equity (ttm)
-68.36%
Revenue (ttm)
18.77M
Net Income Avi to Common (ttm)
-14.31M
Diluted EPS (ttm)
-0.0800
Balance Sheet and Cash Flow
Total Cash (mrq)
2.61M
Total Debt/Equity (mrq)
7.14%
Levered Free Cash Flow (ttm)
-1.25M
Research Analysis: EYE.AX
Analyst Price Targets
Fair Value
No Fair Value available for this ticker
Company Insights: EYE.AX
EYE.AX does not have Company Insights